AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q2 FY25 results · Jul–Sep 2024
AstraZeneca Pharma India reported revenue from operations of ₹408.00 crore (up 31.2% from Q2 FY24) and net profit of ₹38.43 crore (down 26.6% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a standalone basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 408.00 | 311.07 | +31.2% | 387.52 | +5.3% |
| Other income | 8.15 | 8.37 | −2.6% | 8.35 | −2.3% |
| Total income | 416.15 | 319.44 | +30.3% | 395.87 | +5.1% |
| Profit before tax | 51.03 | 73.38 | −30.5% | (15.16) | Turned profit |
| Net profit for the period | 38.43 | 52.37 | −26.6% | (11.79) | Turned profit |
| EPS, basic (₹) | 15.37 | 20.95 | −26.6% | (4.72) | Turned profit |
| Net margin (%) | 9.4 | 16.8 | -3.0 |
Standalone
- Filed with BSE
- 13 Nov 2024, 18:34 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE